Educational Pharmaceutical Care program for Newly Diagnosed Diabetes Mellitus Patients.
Phase 2
- Conditions
- Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
- Registration Number
- CTRI/2024/05/067435
- Lead Sponsor
- Rishita Patel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with Type-II diabetes mellitus.
Patients with HbA1c more than 7%.
Patients who receiving oral hypoglycemic and/or insulin therapy.
Patients who provide written informed consent.
Patients who express willingness to participate in the study.
Exclusion Criteria
Patients who are younger than 18 years (They are legally regarded as dependents and consequently they cannot take decisions of their own).
Pregnant Women.
Patients who will not willing to give consent to participate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in HbA1C levels in intervention groupTimepoint: Reduction in HbA1C levels exactly after 4 Times in each 4 month intervention during 16 month study period
- Secondary Outcome Measures
Name Time Method enhancing patients quality of life in the form of reduction of symptoms <br/ ><br>improving self-management of disease & achieving goal of health promotion & prevention of progression of diabetes mellitusTimepoint: exactly 4 times( each 4 months) Intervention during 16 months study period